Recently, Abbott announced that the U.S. Food and Drug Administration has granted Abbott's rapid detection card Binaxnowovid-19 AgCard emergency use authorization. The test card can be used for qualitative detection of novel coronavirus nucleocapsid protein antigen in nasal swab of patients suspected of coronavirus pneumonia-19.
This test card adopts Abbott's mature lateral flow technology, without any instruments and equipment, and it only takes 15 minutes to get the results. In the data submitted to the FDA, a clinical study conducted by Abbott and several top research universities in the United States showed that the sensitivity and specificity of Binaxnowovid-19 agcard in the first seven days of symptoms were 97. 1% and 98.5%, respectively.
This test card costs $5, which is portable and affordable. Since no equipment is needed, this test card will become an important tool for risk management during the coronavirus pneumonia-19 epidemic, and can be used as the first line of defense to quickly identify and isolate infected people so that they will not spread the disease to others.
Abbott will also launch NAVICA, a supplementary mobile phone application for iPhone and Android devices, which is the first such application and will be provided free of charge. In crowded places, when organizations such as workplaces and schools ask questions, this application will allow people with negative test results to display temporary digital health passes, display BinaxNOW test results to organizers, and update the dates of passes and test results every time a test is conducted by a medical service provider. Organizations will be able to view and verify the information displayed on mobile devices, and combine measures such as hand washing, social distance, enhanced cleaning and wearing masks to facilitate personnel to enter facilities.
Abbott plans to issue tens of millions of test cards in September and reach 50 million test cards per month at the beginning of 10. Since April this year, the company has invested hundreds of millions of dollars in the mass production of BinaxNOW in two new factories in the United States.
Robert B. Ford, President and CEO of Abbott, said: "We specially designed BinaxNOWtest and NAVICA applications to provide comprehensive testing solutions to help Americans have more confidence in their health and life. BinaxNOW and NAVICA applications provide us with an affordable, easy-to-use and extensible test, as well as a complementary digital health tool to help us have a more normal state in our daily lives. "
Dr JosephPetrosino, Chairman of Molecular Virology and Microbiology of Baylor Medical College, said: "The large-scale launch and application of this test card will enable tens of millions of people to obtain fast and reliable tests. According to laboratory tests, you can get excellent sensitivity, but it may take several days or longer to get the results. With rapid antigen testing, you can get the results immediately and let the infected people leave the street and enter the quarantine area, so that the virus will not spread. "
Original source: AbbottsFast, $5 15 minutes, easy-to-use Covid-19 AntigentestReceive SFDA emergency user authorization; mobileappdisplaystestresultstohelpour returntodaylife； Output soared to 50 million times a month.